AbbVie (ABBV)
Develops immunology, neuroscience, oncology, and aesthetics products led by Skyrizi and Rinvoq.
Something off on this page? Send us feedback.
Develops and sells medicines across immunology, neuroscience, oncology, and eye care, plus Botox Cosmetic and other aesthetics products. Skyrizi and Rinvoq now generate roughly half of revenue, making regulatory approvals, market access, and product exclusivity central to the business.
Develops, manufactures, and commercializes prescription medicines across immunology, neuroscience, oncology, and eye care, alongside Allergan Aesthetics products. Skyrizi and Rinvoq anchor immunology; Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta serve neuroscience; Imbruvica, Venclexta, and Elahere cover blood and solid cancers; Botox Cosmetic and Juvederm lead aesthetics. Products are sold worldwide, with the United States generating most revenue.
Pairs internal research with licensing and acquisitions, then uses a global supply chain and commercial network to launch medicines and expand approved uses. Skyrizi and Rinvoq together produce roughly half of recent revenue as Humira declines after biosimilar entry. Sales depend on clinical and regulatory approvals, patent and regulatory exclusivity, payer reimbursement, and access through wholesalers, specialty pharmacies, and healthcare providers.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 10, 2026 | HSBC | Reiterate | Rating: —Target: $300 | Target: $315 |
| Aug 20, 2026 | Piper Sandler | Reiterate | Rating: —Target: $298 | Target: $303 |
| Aug 17, 2026 | Wells Fargo | Reiterate | Rating: —Target: $295 | Target: $300 |
| Aug 13, 2026 | Wolfe Research | Upgrade | Target: $127 | Target: $300 |
| Aug 5, 2026 | Erste Group | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $6.57B · Total debt $70.82B · Total assets $135.13B · Shareholders' equity −$5.94B
- Revenue
- $16.99B
- Operating income
- $6.43B
- Net income
- $3.61B
HistoryDividendAnnual yieldUpcoming
| Institutions | 76.22% | 1.35B shares | |
|---|---|---|---|
| 4,342 holders · as of Jun 30, 2026 | |||
| Insiders | 0.08% | 1.48M shares | |
| 25 holders · as of Aug 18, 2026 | |||
| Strategic holders | 7.26% | 128.20M shares | |
| 2 holders · as of Jul 11, 2025 | |||
| Other | 16.44% | 290.55M shares | |
| remainder | |||
1.77B company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.46% | 149.49M | as of Jun 30, 2026 |
BlackRock, Inc.Strategic | 7.25% | 128.20M | filed Feb 3, 2022 |
Vanguard Capital Management LLCInstitution | 6.53% | 115.40M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.67% | 82.60M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 2.74% | 48.48M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 14, 2026 | Nicholas Donoghoe | officer: EVP, CHIEF BUS/STRAT OFFICER | −32,710 | $250.00 |
| Mar 4, 2026 | David Ryan Purdue | officer: SVP, Controller | −5,230 | $233.56 |
| Mar 2, 2026 | Perry C. Siatis | officer: EVP, GC AND SECRETARY | −18,668 | $234.39 |
| Feb 25, 2026 | Perry C. Siatis | officer: EVP, GC AND SECRETARY | −22,381 | $230.00 |
- Sanofi (ADR)
Dupixent is the world's #1 immunology drug and Skyrizi / Rinvoq's primary rival.
- Johnson & Johnson
Widest immunology-oncology overlap across every AbbVie growth franchise.
- AstraZeneca (ADR)
Calquence takes CLL share from Imbruvica with a cleaner cardiac safety profile.
- Novartis (ADR)
Cosentyx contests Skyrizi in psoriasis and PsA via IL-17A vs IL-23.
- Merck
Keytruda's .5B oncology scale overlaps AbbVie's hematology assets.
- Eli Lilly
Olumiant vs Rinvoq in JAK; Emgality rivals Botox Therapeutic in migraine.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| AbbVie | $263.62 | −0.33% | $467.37B | 74.5 | 17.3 | 7.3 | +10.2% |
| Sanofi (ADR) | $42.20 | −0.70% | $102.05B | 75.6 | — | 1.8 | +11.2% |
| Johnson & Johnson | $265.52 | −1.47% | $649.40B | 31.2 | 22.4 | 6.6 | +6.6% |
| AstraZeneca (ADR) | $167.87 | −0.14% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| Novartis (ADR) | $141.10 | +0.08% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| Merck | $149.21 | −0.19% | $369.24B | 119.6 | 17.3 | 5.6 | +5.1% |
| Eli Lilly | $1,148.23 | −1.43% | $1.10T | 39.1 | 28.1 | 13.8 | +47.7% |
| Median | 35.1 | 17.3 | 5.2 | +6.5% |